Preventive efficacy of six monthly oral doses of Simparica Trio ® , Heartgard ® Plus, and Interceptor ® Plus against a macrocyclic lactone-resistant strain (ZoeLA) of heartworm (Dirofilaria immitis) in dogs

• Published in: Parasites & vectors Vol. 15; no. 1; p. 81
• Main Authors: Myers, Jamie A E, Holzmer, Susan, McCall, John W, Mahabir, Sean P, McTier, Tom L, Maeder, Steven J, Kryda, Kristina
• Format: Journal Article
• Language: English
• Published: England BioMed Central 11.03.2022; BMC
• Subjects: Animals; Azetidines; Canine; Dirofilaria immitis; Dirofilariasis - drug therapy; Dirofilariasis - prevention & control; Dog Diseases - drug therapy; Dog Diseases - prevention & control; Dogs; Heartgard® Plus; Heartworm; Interceptor® Plus; Ivermectin - therapeutic use; Lactones - pharmacology; Macrolides; Pyrantel - pharmacology; Simparica Trio; Spiro Compounds; Interceptor® Plus; Resistance; Laboratory study; Heartgard® Plus; Macrocyclic lactone; Moxidectin; Heartworm; Simparica Trio; Dirofilaria immitis; Canine
• ISSN: 1756-3305; 1756-3305
• DOI: 10.1186/s13071-022-05180-3

Administration of four to six consecutive monthly doses of 24 µg/kg moxidectin alone shows high effectiveness in preventing the maturation of macrocyclic lactone (ML)-resistant heartworm strains, Dirofilaria immitis JYD-34 and ZoeLA. This laboratory study evaluated the efficacy of six consecutive monthly oral doses of Simparica Trio (moxidectin/sarolaner/pyrantel) compared to six monthly doses of either Heartgard Plus (ivermectin/pyrantel) or Interceptor Plus (milbemycin oxime/praziquantel) against ML-resistant D. immitis ZoeLA strain. Beagle dogs were inoculated with 50 third-stage (L3) D. immitis larvae (ZoeLA) 30 days prior to the first treatment. Dogs were randomized to treatment (six animals in each group) with six monthly oral doses of placebo, Simparica Trio, Heartgard Plus, or Interceptor Plus at their respective label doses. Microfilaria (MF) and antigen tests were conducted periodically, and efficacy was evaluated by necropsy for adult heartworms approximately 9 months after L3 inoculation. Adult heartworms were recovered from all six placebo dogs, with a geometric mean of 35.5 worms (range, 23-48). Five of the six dogs treated with Simparica Trio were infected with a geometric mean of 1.0 worms (range, 0-3), and all remained MF-negative. All Heartgard Plus-treated dogs (six) were infected with a geometric mean of 32.5 worms (range, 22-38); five of these dogs were MF-positive at day 236. All Interceptor Plus-treated dogs (six) were infected with a geometric mean of 22.8 worms (range, 10-34); five of these dogs were MF-positive at day 236. The efficacy of six consecutive doses with Simparica Trio, Heartgard Plus, and Interceptor Plus against ZoeLA was 97.2, 8.5, and 35.9%, respectively. Adult worm counts for the Simparica Trio-treated group were significantly lower (P < 0.0001) than placebo control, Heartgard Plus, and Interceptor Plus-treated groups. Adult worm counts for Heartgard Plus and Interceptor Plus were not significantly different from placebo (P > 0.05). Simparica Trio prevented microfilaremia in all dogs and was highly effective (97.2%) and significantly better than either Heartgard Plus (8.5%) or Interceptor Plus (35.9%) in preventing the development of the ZoeLA ML-resistant heartworm strain when administered for six consecutive months in this comparative laboratory efficacy study.